The National Marrow Donor Program's Symposium on Hematopoietic Cell Transplantation in 2020: A Health Care Resource and Infrastructure Assessment

National Marrow Donor Program®, 3001 Broadway Street NE, Minneapolis, MN 55413, USA.
Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation (Impact Factor: 3.15). 12/2011; 18(2):172-82. DOI: 10.1016/j.bbmt.2011.10.004
Source: PubMed

ABSTRACT Hematopoietic cell transplantation (HCT) is the only known curative therapy for many patients with life-threatening hematologic and oncologic diseases. It is estimated that the National Marrow Donor Program(®) (NMDP) will facilitate 10,000 transplants by 2015, double the current number. To better understand the existing personnel and center infrastructure for HCT in the country and to address system capacity challenges to the future growth of HCT, the NMDP convened a diverse group of stakeholders and thought leaders representing HCT physicians, physician assistants, nurse practitioners, nurses, pharmacists, other healthcare providers, HCT program directors, hospital administrators, payors, and professional organizations. Working groups were formed to identify: capacity issues because of shortages in human resources, structural constraints, and patient access barriers including diversity and healthcare disparity challenges; recommendations to address challenges; and stakeholders to engage. This report details the deliberations and recommendations of a national symposium, "Hematopoietic Cell Transplantation in 2020: A Health Care Resource and Infrastructure Assessment," held in September 2010.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Variability in transplant benefits may directly impact outcomes of individuals undergoing autologous or allogeneic hematopoietic stem cell transplantation procedures. The Financial Working Group of the National Marrow Donor Program- sponsored System Capacity Initiative addressed the issue of variable benefits and reviewed multiple transplant benefit packages from both public and private payer organizations. On completion of the review, a consensus was obtained on defining a recipient benefit package that would avoid major coverage gaps that could negatively influence patient outcomes. The recommendation was to encourage adoption of these benefits at a national level by payers, benefit brokers/consultants and sales teams.
    Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation 07/2014; 20(11). DOI:10.1016/j.bbmt.2014.07.007 · 3.15 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Being in work or the equivalent is an important goal after allo-SCT and is used as an indicator of recovery. The aim was to elucidate occupational status and factors associated with work among SCT survivors. Adults in working age with a haematological disease (n=177) were followed up within a median of 8 (range 28) years post allo-SCT. Predictors of not being in work at all or working part-time because of sick leave, disability pension or early old-age pension were analyzed using logistic regression analyses. At diagnosis, 82% of the participants were working full-time and 2% were on sick leave or old-age pension. At follow-up, 52% were working full-time, 27% were working part-time and 17% were on sick leave, disability pension or old-age pension. Not working at all was associated with multi-morbidity (P=0.01) and poorer health (P=0.00). Working part-time was associated with a higher age at diagnosis (P=0.00), being a woman (P=0.03), being born abroad (P=0.03) and multi-morbidity (P=0.00). In conclusion, the majority of survivors were in paid work at follow-up; however, a substantial number were not working or worked part-time.Bone Marrow Transplantation advance online publication, 10 March 2014; doi:10.1038/bmt.2014.26.
    Bone marrow transplantation 03/2014; DOI:10.1038/bmt.2014.26 · 3.00 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: It is anticipated that by the year 2020, the United States will double the number of hematopoietic cell therapy transplants completed in this country. As a freestanding cancer hospital with one of the largest hematopoietic cell therapy transplant programs in the country, City of Hope embarked on an innovative strategy to address current capacity issues and prospectively plan for future expansion of transplant volumes. This article describes the planning process that was undertaken using various content-specific focused teams to address all components of designing and opening an outpatient day hospital suitable for management of patients undergoing transplant in an ambulatory setting. The deliverables of the 11 teams that drove this planning process are addressed.
    Nursing administration quarterly 07/2014; 38(3):206-213. DOI:10.1097/NAQ.0000000000000038